J9317Drugs Administered Other than Oral Method

Injection, sacituzumab govitecan-hziy, 2.5 mg

Short description: Sacituzumab govitecan-hziy

Effective date: January 1, 2021
Termination date: —

Related codes (J-series)

J0013Esketamine, nasal spray J0014Cocaine hcl nasal (goprelto)J0120Tetracyclin injection J0121Inj., omadacycline, 1 mg J0122Inj., eravacycline, 1 mg J0129Abatacept injection J0130Abciximab injection J0131Inj, acetaminophen (nos)J0132Acetylcysteine injection J0133Acyclovir injection J0134Inj acetaminophen -fresenius J0135Adalimumab injection

Frequently asked questions

What is HCPCS code J9317?

J9317 is a HCPCS Level II code for Injection, sacituzumab govitecan-hziy, 2.5 mg.

What category is HCPCS code J9317 in?

J9317 falls under the Drugs Administered Other than Oral Method category of HCPCS Level II.

When did HCPCS code J9317 become effective?

J9317 has been effective since January 1, 2021, per CMS's quarterly HCPCS update.

HCPCS Level II data from CMS (public domain). HCPCS Level I (CPT) codes are not included — CPT is copyrighted by the American Medical Association. Always verify codes with authoritative sources before making coding or billing decisions.